Halozyme Therapeutics, Inc. · San Diego, CA United States ·(NASDAQ (GM): HALO)
Company Description
Halozyme Therapeutics makes enzymes for therapeutic and drug delivery applications. The company's products are based on recombinant human PH20, a human synthetic enzyme it hopes will offer safety benefits over animal-derived versions. The firm's first commercial product, Cumulase, is used for in-vitro fertilization. Another product, Hylenex, is used as an adjuvant for drug and fluid infusions. Products under development include drug delivery agents using the company's Enhanze technology, as well as therapeutic enzymes for cancer, metabolism, and dermatology applications. Halozyme's development partners include
Key Halozyme Therapeutics, Inc. Financials
| Company Type | Public - NASDAQ (GM): HALO Headquarters |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | $8.8 |
| 2008 Employees | 129 |
Halozyme Therapeutics, Inc. Executives
| Title | Name & Bio | Contact |
| Chairman | Kenneth Kelley | Network |
| President, CEO, and Director | Jonathan Lim | Network |
| VP Manufacturing and Operations | William Fallon | Network |
